Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Verrica Parmaceuticals Inc | VRCA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.79 | 04:05:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.79 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.86 - 7.755 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 6.79 | USD |
Verrica Parmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 288.02M | 42.42M | - | 5.12M | -67M | -1.58 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Verrica Parmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRCA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.06 | 7.06 | 6.57 | 6.85 | 168,151 | -0.27 | -3.82% |
| 1 Month | 5.70 | 7.32 | 5.58 | 6.73 | 171,827 | 1.09 | 19.12% |
| 3 Months | 5.67 | 7.32 | 4.60 | 5.88 | 135,911 | 1.12 | 19.75% |
| 6 Months | 3.70 | 7.51 | 2.86 | 5.93 | 629,308 | 3.09 | 83.51% |
| 1 Year | 6.51 | 7.755 | 2.86 | 5.75 | 461,358 | 0.28 | 4.30% |
| 3 Years | 13.63 | 14.789 | 1.77 | 5.66 | 263,598 | -6.84 | -50.18% |
| 5 Years | 9.97 | 18.67 | 1.77 | 6.68 | 193,125 | -3.18 | -31.90% |
Verrica Parmaceuticals Description
| Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. |
